Perfusion MR Imaging in Gliomas: Comparison with Histologic Tumor Grade

Overview

Journal Korean J Radiol

Specialty Radiology

Date 2001 Dec 26

PMID 11752962

Citations 20

Authors

S J Lee

J H Kim

Y M Kim

G K Lee

E J Lee

I S Park

J M Jung

K H Kang

T Shin

Affiliations

Soon will be listed here.

Abstract

Objective: To determine the usefulness of perfusion MR imaging in assessing the histologic grade of cerebral gliomas.

Materials And Methods: In order to determine relative cerebral blood volume (rCBV), 22 patients with pathologically proven gliomas (9 glioblastomas, 9 anaplastic gliomas and 4 low-grade gliomas) underwent dynamic contrast-enhanced T2*-weighted and conventional T1- and T2-weighted imaging. rCBV maps were obtained by fitting a gamma-variate function to the contrast material concentration versus time curve. rCBV ratios between tumor and normal white matter (maximum rCBV of tumor / rCBV of contralateral white matter) were calculated and compared between glioblastomas, anaplastic gliomas and low-grade gliomas.

Results: Mean rCBV ratios were 4.90 degrees +/- 1.01 for glioblastomas, 3.97 degrees +/- 0.56 for anaplastic gliomas and 1.75 degrees +/-1.51 for low-grade gliomas, and were thus significantly different; p <.05 between glioblastomas and anaplastic gliomas, p <.05 between anaplastic gliomas and low-grade gliomas, p <.01 between glioblastomas and low-grade gliomas. The rCBV ratio cutoff value which permitted discrimination between high-grade (glioblastomas and anaplastic gliomas) and low-grade gliomas was 2.60, and the sensitivity and specificity of this value were 100% and 75%, respectively.

Conclusion: Perfusion MR imaging is a useful and reliable technique for estimating the histologic grade of gliomas.

Citing Articles

Distinction of pseudoprogression from true progression in glioblastomas using machine learning based on multiparametric magnetic resonance imaging and O-methylguanine-methyltransferase promoter methylation status.

Yadav V, Mohan S, Agarwal S, de Godoy L, Rajan A, Nasrallah M Neurooncol Adv. 2024; 6(1):vdae159.

PMID: 39502470 PMC: 11535496. DOI: 10.1093/noajnl/vdae159.

A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007.

Zalles M, Smith N, Saunders D, Lerner M, Fung K, Battiste J J Cell Mol Med. 2021; 26(2):570-582.

PMID: 34910361 PMC: 8743651. DOI: 10.1111/jcmm.17133.

Multiparametric MRI assessment of response to convection-enhanced intratumoral delivery of MDNA55, an interleukin-4 receptor targeted immunotherapy, for recurrent glioblastoma.

Mohan S, Wang S, Chawla S, Abdullah K, Desai A, Maloney E Surg Neurol Int. 2021; 12:337.

PMID: 34345478 PMC: 8326072. DOI: 10.25259/SNI_353_2021.

In vivo quantification of mandibular bone remodeling and vascular changes in a Wistar rat model: A novel HR-MRI and micro-CT fusion technique.

Song D, Shujaat S, Zhao R, Huang Y, Shaheen E, Van Dessel J Imaging Sci Dent. 2020; 50(3):199-208.

PMID: 33005577 PMC: 7506089. DOI: 10.5624/isd.2020.50.3.199.

Exploring Two Methods of CBV Estimation in Two Groups of Grade III Gliomas with Different Appearance on Post-Contrast T1 Images.

B V, S M, R V, F M, M Y J Biomed Phys Eng. 2020; 10(3):283-290.

PMID: 32637372 PMC: 7321391. DOI: 10.31661/jbpe.v0i0.1176.

References

Wenz F, Rempp K, Hess T, Debus J, Brix G, Engenhart R . Effect of radiation on blood volume in low-grade astrocytomas and normal brain tissue: quantification with dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol. 1996; 166(1):187-93. DOI: 10.2214/ajr.166.1.8571873. View

Edelman R, Siewert B, Darby D, Thangaraj V, Nobre A, Mesulam M . Qualitative mapping of cerebral blood flow and functional localization with echo-planar MR imaging and signal targeting with alternating radio frequency. Radiology. 1994; 192(2):513-20. DOI: 10.1148/radiology.192.2.8029425. View

Sugahara T, Korogi Y, Kochi M, Ikushima I, Hirai T, Okuda T . Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol. 1998; 171(6):1479-86. DOI: 10.2214/ajr.171.6.9843274. View

Knopp E, Cha S, Johnson G, Mazumdar A, Golfinos J, Zagzag D . Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology. 1999; 211(3):791-8. DOI: 10.1148/radiology.211.3.r99jn46791. View

THOMPSON Jr H, Starmer C, Whalen R, McIntosh H . INDICATOR TRANSIT TIME CONSIDERED AS A GAMMA VARIATE. Circ Res. 1964; 14:502-15. DOI: 10.1161/01.res.14.6.502. View

Cha S, Knopp E, Johnson G, Litt A, Glass J, Gruber M . Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol. 2000; 21(5):881-90. PMC: 7976741. View

Sugahara T, Korogi Y, Tomiguchi S, Shigematsu Y, Ikushima I, Kira T . Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol. 2000; 21(5):901-9. PMC: 7976740. View

Brem S, COTRAN R, Folkman J . Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst. 1972; 48(2):347-56. View

Joyce P, Bentson J, Takahashi M, Winter J, Wilson G, Byrd S . The accuracy of predicting histologic grades of supratentorial astrocytomas on the basis of computerized tomography and cerebral angiography. Neuroradiology. 1978; 16:346-8. DOI: 10.1007/978-3-642-66959-0_114. View

10.

Seeger J, Burke D, Knake J, Gabrielsen T . Computed tomographic and angiographic evaluation of hemangioblastomas. Radiology. 1981; 138(1):65-73. DOI: 10.1148/radiology.138.1.7192875. View

11.

Van Kirk O, CORNELL S, Jacoby C . Posterior fossa intra-axial tumors: a comparison of computed tomography with other imaging methods. J Comput Tomogr. 1979; 3(1):31-9. DOI: 10.1016/0149-936x(79)90058-4. View

12.

Rosen B, Belliveau J, Vevea J, Brady T . Perfusion imaging with NMR contrast agents. Magn Reson Med. 1990; 14(2):249-65. DOI: 10.1002/mrm.1910140211. View

13.

Edelman R, Mattle H, Atkinson D, Hill T, Finn J, MAYMAN C . Cerebral blood flow: assessment with dynamic contrast-enhanced T2*-weighted MR imaging at 1.5 T. Radiology. 1990; 176(1):211-20. DOI: 10.1148/radiology.176.1.2353094. View

14.

Belliveau J, Rosen B, KANTOR H, Rzedzian R, Kennedy D, McKinstry R . Functional cerebral imaging by susceptibility-contrast NMR. Magn Reson Med. 1990; 14(3):538-46. DOI: 10.1002/mrm.1910140311. View

15.

Rosen B, Belliveau J, Aronen H, Kennedy D, Buchbinder B, FISCHMAN A . Susceptibility contrast imaging of cerebral blood volume: human experience. Magn Reson Med. 1991; 22(2):293-9; discussion 300-3. DOI: 10.1002/mrm.1910220227. View

16.

Aronen H, Cohen M, Belliveau J, Fordham J, Rosen B . Ultrafast imaging of brain tumors. Top Magn Reson Imaging. 1993; 5(1):14-24. View

17.

Le Bihan D, Douek P, Argyropoulou M, Turner R, Patronas N, Fulham M . Diffusion and perfusion magnetic resonance imaging in brain tumors. Top Magn Reson Imaging. 1993; 5(1):25-31. View

18.

Maeda M, Itoh S, Kimura H, Iwasaki T, Hayashi N, Yamamoto K . Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging. Radiology. 1993; 189(1):233-8. DOI: 10.1148/radiology.189.1.8372199. View

19.

Aronen H, Gazit I, Louis D, Buchbinder B, Pardo F, Weisskoff R . Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology. 1994; 191(1):41-51. DOI: 10.1148/radiology.191.1.8134596. View

20.

Guckel F, Brix G, Rempp K, Deimling M, Rother J, Georgi M . Assessment of cerebral blood volume with dynamic susceptibility contrast enhanced gradient-echo imaging. J Comput Assist Tomogr. 1994; 18(3):344-51. DOI: 10.1097/00004728-199405000-00002. View